<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01584505</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-1107-PR-0067</org_study_id>
    <secondary_id>2011-004759-37</secondary_id>
    <nct_id>NCT01584505</nct_id>
  </id_info>
  <brief_title>Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD</brief_title>
  <acronym>CARSAF</acronym>
  <official_title>Randomized, Double-Blind, Active Controlled, 3-Arm Parallel Group, Multi-National, Multi-Centre Study To Evaluate The Cardiac Safety Of Two Doses Of CHF5993 BID Delivered Via HFA PMDI Both Combined With CHF1535 BID Delivered Via HFA PMDI Versus CHF1535 BID Delivered Via HFA PMDI In Patients With Moderate To Severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac Safety Study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to demonstrate equivalence between CHF1535 plus CHF5992 (two&#xD;
      different dosages) over CHF1535 alone in change from baseline in average 24-hour heart rate,&#xD;
      as primary end point, and other ECG parameters.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in average 24-hour heart rate at Final visit</measure>
    <time_frame>Day 14 of study treatment</time_frame>
    <description>To assess the effect on change from baseline in average 24h Heart Rate at Day 14 of study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Rate and ECG parameters variation</measure>
    <time_frame>Day 1 and Day 14 of Study Treatment</time_frame>
    <description>Pre and post-dose</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">191</enrollment>
  <condition>Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>CHF5993 HFA pMDI dose 1, BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF5993 HFA pMDI dose 1, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF5993 HFA pMDI dose 2, BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHF5993 HFA pMDI dose 2, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF1535 HFA pMDI + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CHF1535 HFA pMDI BID plus placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF1535 + CHF5992 dose 1 BID</intervention_name>
    <description>CHF1535 + CHF5992 dose 1 BID for 14 days</description>
    <arm_group_label>CHF5993 HFA pMDI dose 1, BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF1535 + CHF5992 dose2 BID</intervention_name>
    <description>CHF1535 + CHF5992 dose 2 BID for 14 days</description>
    <arm_group_label>CHF5993 HFA pMDI dose 2, BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF1535 daily dose</intervention_name>
    <description>CHF1535 daily dose for 14 days</description>
    <arm_group_label>CHF1535 HFA pMDI + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female adults ≥ 40years and ≤ 80years old&#xD;
&#xD;
          2. Male subjects: they and/or their partner must be willing to use an approved method of&#xD;
             contraception 1) from the time of dose administration and until 30 days after the last&#xD;
             dose of study. Subjects must not donate sperm for 30 days after the last dose of study&#xD;
             drug&#xD;
&#xD;
          3. Written informed consent obtained by the patient prior to any study related procedures&#xD;
&#xD;
          4. Outpatient with diagnosis of COPD (defined in GOLD guidelines, up to date 2010) at&#xD;
             least in the 6 months before the screening visit, including:&#xD;
&#xD;
               -  Smoking history of at least 10 pack years defined as [(number of cigarettes&#xD;
                  smoked per day) x (number of years of smoking)]/20; both current and ex smokers&#xD;
                  are eligible. For patients who are in smoking cessation therapy this must be&#xD;
                  completed at least 1 week before study enrollment&#xD;
&#xD;
               -  Regular use of bronchodilators (e.g. β2-agonist or/and anticholinergics) in the&#xD;
                  previous 2 months at Visit 0&#xD;
&#xD;
               -  Post-bronchodilator FEV1 ≥ 30% and ≤ 60% of the predicted normal value&#xD;
&#xD;
               -  Post-bronchodilator FEV1/FVC ≤ 0.70&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women or all women physiologically capable of becoming pregnant&#xD;
             UNLESS they meet the following definition of postmenopausal: 12 months of natural&#xD;
             (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with already documented&#xD;
             serum FSH level &gt; 40mlU/mL or are using one of the following acceptable methods of&#xD;
             contraception&#xD;
&#xD;
               -  Surgical sterilization (e.g. bilateral tubal ligation, hysterectomy)&#xD;
&#xD;
               -  Hormonal contraception (implantable, patch, oral)&#xD;
&#xD;
               -  Double-barrier methods (any double combination of: IUD, male or female condom&#xD;
                  with spermicidal gel, diaphragm, sponge, cervical cap) Reliable contraception&#xD;
                  should be maintained throughout the study and for 30 days after study drug&#xD;
                  discontinuation&#xD;
&#xD;
          2. Current diagnosis of asthma or other respiratory disorders (other than COPD) which may&#xD;
             interfere with data interpretation according to the investigator's opinion&#xD;
&#xD;
          3. Hospitalization due to COPD exacerbation in the three months prior to screening and&#xD;
             during run-in period or COPD exacerbation requiring systemic steroids and or&#xD;
             antibiotics in the 6 weeks prior to screening and during run-in period. COPD&#xD;
             exacerbation will be defined according to the following criteria: a sustained&#xD;
             worsening of the patient condition (dyspnoea, cough and/or sputum&#xD;
             production/purulence), from the stable state and beyond normal day-to-day variations,&#xD;
             that is acute in onset and necessitates a change in regular medication that includes&#xD;
             prescription of oral corticosteroids and/or antibiotics, or need for hospitalization.&#xD;
&#xD;
          4. Patient with COPD who requires regular long term use of oxygen therapy&#xD;
&#xD;
          5. Patient who requires chronic mechanical ventilation for COPD&#xD;
&#xD;
          6. Patient treated regularly with oral or parenteral corticosteroids for their COPD&#xD;
&#xD;
          7. Change of COPD regular medication in the 4 weeks prior to enrollment&#xD;
&#xD;
          8. Unstable CV diseases&#xD;
&#xD;
          9. Known abnormality of any cardiac valve&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Jörg Kampschulte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arzt für Innere Medizin und Pneumologie, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital &quot;Lozenets&quot;</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Kampschulte</name>
      <address>
        <city>Berlin</city>
        <zip>D-12165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fővárosi Önkormányzat Szent János Kórháza és Észak-budai Egyesített Kórházai Tüdőgondozó Szakrendelő</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISPL Centrum Medyczne Robert M. Mróz</name>
      <address>
        <city>Białystok</city>
        <zip>15-003</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Moscow city</name>
      <address>
        <city>Moscow</city>
        <zip>127018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicines Evaluation Unit, Langley Building</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004759-37</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <link>
    <url>https://www.chiesi.com/clinic/CSR_Synopsis_CCD-1107-PR-0067.pdf</url>
    <description>CSR Synopsis available in the CHIESI Clinical Study Register</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 23, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information.&#xD;
Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.</ipd_description>
    <ipd_access_criteria>Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.</ipd_access_criteria>
    <ipd_url>https://www.chiesi.com/en/chiesi-clinical-trial-data-request-portal/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

